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Abstract 
Introduction The tyrosine kinase inhibitor sunitinib has dramatically improved cancer therapy in 
recent years however, this success has been marred by reports of associated cardiotoxicity. The 
effect of sunitinib on cardiac myocyte function has been extensively studied, yet little is known of 
wider ranging effects on cardiac non-myocytes. Cardiac fibroblasts (CF) are the most abundant cell 
type within the heart and are responsible for maintaining cardiac structure via extracellular matrix 
remodelling and for facilitating synchronised cardiac contraction. Here, we have investigated 
whether chronic sunitinib treatment adversely affects CF viability. 
Methods CFs were isolated from adult male Sprague-Dawley rats (aged 10 weeks, weighing 350–
450 g) via bulk collagenase digestion and were maintained in culture before treatment with sunitinib 
(0.1–10 µM) for 18 hour in the presence of serum (DMEM supplemented with 20% FBS). Cell 
phenotype and growth were imaged using a Leica EC3 digital camera affixed to a Leica DM IL LED 
inverted microscope. MTT assays and FACS were used to assess cell viability. Data is presented as 
mean values±SD of n observations, where n represents the number of samples. Comparisons were 
assessed by one-way ANOVA with post hoc Dunnett’s test. 
Results Cell imaging indicated visible alterations in fibroblast phenotype following 3 µM sunitinib 
treatment with significant cell loss at 10 µM. Assessment of CF viability via MTT assays showed a 
significant reduction in viable cells following treatment with 10 µM sunitinib (74.02%±4.53% vs 
94.12%±6.95% (% viable cells, sunitinib vs vehicle), n=4, p=0.0002). Further analysis via FACS 
confirmed these MTT findings, showing a dose-dependent reduction in the percentage of healthy 
cells following drug treatment (44.00%±14.49% vs 95.83%±2.06% (% healthy cells, 3 µM sunitinib vs 
vehicle), n=3, p=0.0001) and (1.25%±0.50% vs 95.83%±2.06% (10µM sunitinib vs vehicle), n=3, 
p=0.0001). An increase in the number of late apoptotic (17.56%±13.38% vs 1.13%±0.43% (% late 
apoptotic cells, sunitinib vs vehicle), n=3, p=0.004) and necrotic cells (56.33%±36.57% vs 
1.69%±2.55% (% necrotic cells, sunitinib vs vehicle), n=3, p=0.0002) at 10 µM sunitinib was also 
observed. 
Conclusions Sunitinib causes a dose dependent decrease in CF viability with significant effects 
observed at concentrations as low as 3 µM. These results suggest that the cardiotoxic effects of 
sunitinib are likely to impact on both contractile and non-contractile cells of the heart. Further work 
is under way to assess how clinical doses can alter CF function. This may enhance understanding 
towards mechanisms related to sunitinib-induced cardiotoxicity. 
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